NASDAQ:PCYC - Pharmacyclics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pharmacyclics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pharmacyclics, Inc is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:PCYC Previous Symbol CUSIP71693310 CIK949699 WebN/A Phone+1-302-6587581Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive PCYC News and Ratings via Email Sign-up to receive the latest news and ratings for PCYC and its competitors with MarketBeat's FREE daily newsletter. Pharmacyclics (NASDAQ:PCYC) Frequently Asked Questions What is Pharmacyclics' stock symbol? Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC." Has Pharmacyclics been receiving favorable news coverage? News headlines about PCYC stock have been trending neutral on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Pharmacyclics earned a news impact score of 0.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for Pharmacyclics. Who are some of Pharmacyclics' key competitors? Some companies that are related to Pharmacyclics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Pharmacyclics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmacyclics investors own include Celgene (CELG), Gilead Sciences (GILD), Baidu (BIDU), Regeneron Pharmaceuticals (REGN), Netflix (NFLX), Jazz Pharmaceuticals (JAZZ), Biogen (BIIB), Cara Therapeutics (CARA), Intercept Pharmaceuticals (ICPT) and Ionis Pharmaceuticals (IONS). How can I contact Pharmacyclics? Pharmacyclics' mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581. MarketBeat Community Rating for Pharmacyclics (NASDAQ PCYC)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 469 (Vote Outperform)Underperform Votes: 401 (Vote Underperform)Total Votes: 870MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe PCYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCYC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: What does a market perform rating mean?